Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Strong-Buy” by BidaskClub
Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a report released on Saturday, October 26th, BidAskClub reports.
A number of other equities analysts have also recently issued reports on LXRX. Wedbush restated a “buy” rating and issued a $17.00 target price on shares of Lexicon Pharmaceuticals in a report on Friday, October 4th. Citigroup decreased their target price on Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, July 30th. ValuEngine upgraded Lexicon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a repo ...